Quick Answer
Skye Bioscience, Inc. reported Net Income of -$55.92 million for fiscal year 2025.
Skye Bioscience, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$55.92M -110.5% |
-$26.57M +29.4% |
-$37.64M -93.2% |
-$19.48M -128.6% |
-$8.52M -29.9% |
-$6.56M -723.7% |
| Diluted EPS | -$1.41 -93.2% |
-$0.73 +86.4% |
-$5.37 +38.8% |
-$8.77 -43750.0% |
-$0.02 +33.3% |
-$0.03 +40.0% |
| Total Assets | $28.31M -61.1% |
$72.76M +509.4% |
$11.94M +31.1% |
$9.11M -7.5% |
$9.86M +268.9% |
$2.67M +33.8% |
| Cash and Equivalents | $5.88M -91.4% |
$68.42M +5345.1% |
$1.26M | — | — | — |
| Stockholders Equity | $20.02M -70.6% |
$68.15M +3296.9% |
-$2.13M +29.1% |
-$3.01M -151.3% |
$5.86M +1200.9% |
$450.8K -17.7% |
| R&D Expense | — | — | — | $6.01M +105.1% |
$2.93M +50.8% |
$1.94M -13.1% |
| Operating Income | -$58.16M -92.6% |
-$30.19M +13.1% |
-$34.74M -89.7% |
-$18.31M -133.3% |
-$7.85M -24.8% |
-$6.29M +5.2% |
| Shares Outstanding | 33.38M +7.8% |
30.97M +150.8% |
12.35M +238.0% |
3.65M -99.2% |
476.11M +65.3% |
288.07M +57.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$12.75M | -227.2% | +27.6% |
| Diluted EPS | September 30, 2025 | -$0.32 | -220.0% | +27.3% |
| Total Assets | September 30, 2025 | $41.32M | -49.3% | -20.8% |
| Cash and Equivalents | September 30, 2025 | $18.44M | -72.6% | -22.6% |
| Long-Term Debt | September 30, 2020 | $45.6K | — | -29.9% |
| Stockholders Equity | September 30, 2025 | $32.84M | -56.7% | -24.8% |
| R&D Expense | June 30, 2023 | $1.79M | +25.3% | +50.9% |
| Operating Income | September 30, 2025 | -$13.26M | -167.0% | +27.3% |
| Shares Outstanding | September 30, 2025 | 30.99M | +2.1% | +0.0% |
- Skye Bioscience, Inc. reported Net Income of -$55.92 million for fiscal year 2025.
- Skye Bioscience, Inc. showed a decrease of -110.5% in Net Income compared to the prior fiscal year.
- Skye Bioscience, Inc. reported Diluted EPS of $1.41 per share (loss) for fiscal year 2025.
- Skye Bioscience, Inc. showed a decrease of -93.2% in Diluted EPS compared to the prior fiscal year.
- Skye Bioscience, Inc. reported Total Assets of $28.31 million for fiscal year 2025.
- Skye Bioscience, Inc. showed a decrease of -61.1% in Total Assets compared to the prior fiscal year.
- Skye Bioscience, Inc. reported Cash and Equivalents of $5.88 million for fiscal year 2025.
- Skye Bioscience, Inc. showed a decrease of -91.4% in Cash and Equivalents compared to the prior fiscal year.
- Skye Bioscience, Inc. reported Stockholders Equity of $20.02 million for fiscal year 2025.
- Skye Bioscience, Inc. showed a decrease of -70.6% in Stockholders Equity compared to the prior fiscal year.
- Skye Bioscience, Inc. reported R&D Expense of $6.01 million for fiscal year 2022.
- Skye Bioscience, Inc. showed an increase of +105.1% in R&D Expense compared to the prior fiscal year.
- Skye Bioscience, Inc. reported Operating Income of -$58.16 million for fiscal year 2025.
- Skye Bioscience, Inc. showed a decrease of -92.6% in Operating Income compared to the prior fiscal year.
- Skye Bioscience, Inc. reported Shares Outstanding of 33.38 million shares for fiscal year 2025.
- Skye Bioscience, Inc. showed an increase of +7.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: